• EZ Cap™ EPO mRNA (ψUTP): Stability and Neurorepair Benchmark

  2026-07-06

  EZ Cap™ EPO mRNA (ψUTP) is a high-purity, Cap 1-capped human erythropoietin mRNA engineered for robust translation and superior stability. The product leverages pseudouridine modification and enzymatic capping to enhance protein expression and minimize immune activation. This dossier details mechanistic, benchmarking, and workflow evidence supporting its use in neurorepair and erythropoiesis research.

• Moesin as a Diagnostic Biomarker of Endothelial Injury in Se

  2026-07-06

  The reference study identifies moesin (MSN) as a novel and quantifiable biomarker of endothelial injury in sepsis, demonstrating its correlation with disease severity and key inflammatory pathways. These findings highlight MSN’s potential for early diagnosis and severity assessment in clinical and experimental sepsis models.

• Rucaparib (AG-014699): Protocol Optimization in DNA Damage R

  2026-07-05

  Rucaparib (AG-014699) stands out in DNA damage response research, enabling precision radiosensitization and mechanistic insight in cancer models with DNA repair vulnerabilities. Discover best-practice workflows, troubleshooting tips, and the latest findings on apoptosis and transcriptional interplay to elevate your experimental outcomes.

• DRP1 Activation Drives Mitochondrial Fission and Glycolysis

  2026-07-04

  This study demonstrates that hyperoxia-induced DRP1 activation leads to mitochondrial fission and glycolytic reprogramming in alveolar type II (ATII) cells, contributing to the pathogenesis of bronchopulmonary dysplasia (BPD). The findings identify DRP1 as a potential therapeutic target and clarify the mechanistic links between mitochondrial dynamics and metabolic alterations in neonatal lung injury.

• Nitrocefin in β-Lactamase Assays: Protocols, Applications, a

  2026-07-03

  Nitrocefin, a gold-standard chromogenic cephalosporin substrate, enables rapid and precise colorimetric detection of β-lactamase activity, streamlining antibiotic resistance research and inhibitor screening. This article distills cutting-edge experimental workflows and troubleshooting strategies, translating recent pathogen research and advanced protocols into actionable guidance for modern microbiology labs.

• O-GlcNAcylation Links Wnt Signaling to Bone Formation via Gl

  2026-07-03

  This study reveals that Wnt3a-driven bone formation relies on dynamic O-GlcNAcylation, which rewires aerobic glycolysis in osteoblasts. The findings clarify how metabolic regulation via O-GlcNAcylation is essential for Wnt-induced osteogenesis, providing mechanistic insight into bone anabolism with potential implications for osteoporosis research.

• AZD3463 and the Next Chapter of Translational ALK/IGF1R Rese

  2026-07-02

  This thought-leadership article explores the mechanistic, experimental, and strategic dimensions of AZD3463—a dual ALK/IGF1R inhibitor—within the context of translational neuroblastoma research. It provides actionable guidance for targeting the PI3K/AKT/mTOR axis, overcoming resistance, and optimizing combination therapies, while situating AZD3463's unique value proposition in the evolving landscape of pathway-targeted oncology.

• Cy5 Goat Anti-Rabbit IgG (H+L) Antibody: Signal Amplificatio

  2026-07-02

  Explore how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody advances fluorescence-based detection in antiviral immunity research. This article uniquely bridges molecular immunology and practical assay optimization, offering deep insight into assay sensitivity and protocol design.

• Nascent Cone Precursors as the Origin of Human Retinoblastom

  2026-07-01

  This study establishes, using RB1-deficient retinal organoids, that ATOH7+/RXRγ+ nascent cone precursors are the earliest and primary cellular origin of human retinoblastoma. These findings provide new mechanistic insights into tumor initiation and offer refined targets for future therapeutic strategies in ocular oncology.

• DeferoxamineB: Strategic Iron Chelation in Translational Onc

  2026-07-01

  This article explores how Deferoxamine (DeferoxamineB) advances cancer research by modulating ferroptosis and cuproptosis, integrating mechanistic insights with practical guidance for translational scientists. Drawing from state-of-the-art metabolic intervention studies, we position DeferoxamineB as a pivotal tool for designing next-generation assays and therapeutic strategies that target iron metabolism, regulated cell death, and tumor immunity.

• Structural Insights into FADD-Procaspase-8-cFLIP Complex Ass

  2026-06-30

  This study provides the first atomic-resolution structures of human FADD-procaspase-8-cFLIP complexes, elucidating the mechanisms of death-effector domain (DED) assembly in apoptosis and necroptosis regulation. These insights advance understanding of how these complexes fine-tune cell fate decisions, with implications for cancer research targeting apoptotic pathways.

• AI-10-49: Precision CBFβ-SMMHC Inhibitor for AML Research

  2026-06-30

  AI-10-49, a potent CBFβ-SMMHC inhibitor, enables targeted disruption of leukemia-driving fusion proteins, restoring RUNX1 activity in acute myeloid leukemia research. Integrating high specificity and robust in vitro and in vivo activity, it unlocks advanced experimental workflows for dissecting leukemogenic transcriptional programs.

• Ibotenic Acid: Advancing Neurodegenerative Disease Modeling

  2026-06-29

  Explore how ibotenic acid, a dual NMDA and metabotropic glutamate receptor agonist, is redefining neurodegenerative disease modeling and pain circuit research. This article delivers mechanistic insights, strategic guidance for translational neuroscience, and highlights APExBIO’s high-purity ibotenic acid as a pivotal research tool.

• Quinolone–Coumarin Hybrids and Novobiocin Against T. gondii

  2026-06-29

  This study introduces quinolone–coumarin hybrids derived from fluoroquinolones and Novobiocin as promising antiparasitic agents against Toxoplasma gondii. The findings highlight their superior selectivity and reduced cytotoxicity compared to standard therapies, providing a potential new direction for anti-Toxoplasma drug development.

• Metabolic Intervention Enhances Ferroptosis and Cuproptosis

  2026-06-28

  This study introduces a nanosystem-based metabolic intervention that synchronously sensitizes tumor cells to ferroptosis and cuproptosis by inhibiting glycolysis and NAD+ metabolism. The approach enhances anti-tumor immunity and demonstrates a promising strategy for regulated cell death-based cancer therapies.

11861 records 1/791 page Next 12345 下5页 Last page